Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Lead Discovery Center Gmbh

Herbert Waldmann

Gunther Zischinsky

Peter Nussbaumer

Alfred Wittinghofer

Pablo Antonio Martin-Gago

Sandip Murarka

Christian Klein

Philippe Bastiaens

Eyad Kalawy Fansa

Melanie Schwalfenberg

Elena Sabrina Reckzeh

George Karageorgis

Slava Ziegler

Javier De Ceballos Cerrajeria

Pablo Antonio MARTÍN-Gago

The present invention relates to 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds and pharmaceutically acceptable salts thereof as selective inhibitor of glucose transporters 1 and 3 (GLUTs 1 and 3), to methods of preparing said compounds, and to the use thereof as pharmaceutically active agents, especially for the prophylaxis and/or treatment of metabolic diseases, immunological diseases, autoimmune diseases, inflammation, graft versus host disease, cancer, and metastasis thereof. Furthermore, the present invention is directed to pharmaceutical composition comprising at least one of 2,6-methanobenzo[g][1]oxacin-4-one compounds and their analog compounds.

Inhibitors of glucose transporters (GLUTs)

The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said substituted benzene disulfonamides are binding to the prenyl binding pocket of PDE6&#x3b4; and therefore, are useful for the prophylaxis and treatment of cancer by inhibition of the binding of PDE6&#x3b4; to farnesylated Ras proteins and thereby, inhibition of oncogenic Ras signaling in cells.

Benzene disulfonamide for the treatment of cancer

Growing community of inventors

Dortmund, Germany

Herbert Waldmann